Dacomitinib Hydrate is an oral tyrosine kinase inhibitor belonging to the epidermal growth factor receptor (EGFR) inhibitor class, primarily indicated for the treatment of non-small-cell lung carcinoma… Read more
Dacomitinib Hydrate is an oral tyrosine kinase inhibitor belonging to the epidermal growth factor receptor (EGFR) inhibitor class, primarily indicated for the treatment of non-small-cell lung carcinoma and other EGFR-driven malignancies. To support rigorous quality control and pharmaceutical research, this category provides essential tools for the analytical scientist, including reference standards of the active pharmaceutical ingredient, pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These high-quality materials are critical for accurate impurity profiling, the validation of analytical methods such as HPLC and LC-MS, and the quantification of drug levels during pharmacokinetic studies. By utilizing these characterized standards, laboratories can ensure compliance with regulatory requirements and maintain precision throughout the drug development and manufacturing lifecycle, facilitating reliable assessment of drug substance integrity and stability.